Annals of Diagnostic Pathology
Volume 14, Issue 3 , Pages 153-161 , June 2010

Immunohistochemical study of syndecan-1 down-regulation and the expression of P35 protein in oral lichen planus: a clinicopathologic correlation with hepatitis C infection in the Egyptian population

References 

  1. Boyd AS, Neldner KH. Lichen planus. J Am Acad Dermatol. 1991;25:593–619
  2. Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. Number V oral lichen planus: clinical features and management. Oral Dis. 2005;11:338–349
  3. Miller TN, Gibberd DB. Myasthenia gravis, ulcerative colitis and lichen planus. Proc. R. Soc. Med. 1971;64:37–38
  4. Collet E, Dalac S, Brichon P, et al. The association of lichen planus and primary Gougerot-Sjogren syndrome. Ann. Dermatol. Venereol. 1989;116:483–486
  5. Scully C, Porter SR, Eveson JW. Oral lichen planus and coeliac disease (letter). Lancet. 1993;341:1660
  6. Sigurgeirsson B, Lindelof B. Lichen planus and malignancy. Arch Dermatol. 1991;127:1684–1688
  7. Barnes L, Eveson JW. Reic pathology and genetic. World Health Organization classification of tumors. In:  hart P,  Sidransky D editor. Head and neck tumors. Lyon (France): LARC press; 2005;p. 430
  8. Neville BW, Damm DD, Allen CM, Bouquot JE. Oral and maxillofacial pathology. 2nd ed. Philadelphia: WB Saunder; 2004;
  9. Brant JM, Vasconcelos AC, Rodrigues LV. Role of apoptosis in erosive and reticular oral lichen planus exhibiting variable epithelial thickness. Braz Dent J. 2008;19(3):179–185
  10. Zhao ZZ, Savage NW, Sugerman PB, Walsh LJ. Mast cell/T-cell interactions in oral lichen planus. J Oral Pathol Med. 2002;31:189–195
  11. Figueiredo LC, Carrilho FJ, de Andrade HF, Migliari DA. Oral lichen planus and hepatitis C virus infection. Oral Diseases. 2002;8:42–46
  12. Romero MA, Seoane J, Varela-Centelles P, Diz-Dios P, Otero XL. Clinical and pathological characteristics of oral lichen planus in hepatitis C-positive and -negative patients. Clin Otolaryngol. 2002;27:22–26
  13. World Health Organization . Hepatitis C-global prevalence (update). Wkly Epidemiol Rec. 1999;135:1410–1413
  14. Wasely A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20:1–16
  15. Vescovi P, Manfredi M, Savi A, Bonanini M. Neoplastic transformation of oral lichen planus. II: association with risk co-factors. Minerva Stomatol. 2000;49:257–266
  16. Bernfield M, Sanderson RD. Syndecan, a developmentally regulated cell surface proteoglycan that binds extracellular matrix and growth factors. Philos Trans R Soc Lond B Biol Sci. 1990;327(1239):171–186
  17. Inki P, Larjava H, Haapasalmi K, Miettinen HM, Grenman R, Jalkanen M. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes. Eur J Biol. 1994;63(1):43–51
  18. Stanley MJ, Liebersbach BF, Liu W, Anhalt DJ, Sanderson RD. Heparan sulfate-mediated cell aggregation. Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells. J Biol Chem. 1995;270(10):5077–5083
  19. Inki P, Jalkanen M. The role of syndecan-1 in malignancies. Ann Med. 1996;28(1):63–67
  20. Reiland J, Sanderson RD, Waguespack M, Barker SA, Long R, Carson DD, et al. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J Biol Chem. 2004;279:8047–8055
  21. Tsanou E, Ioachim E, Briasoulis E, Charchanti A, Damala K, Karavasilis V, et al. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. Correlation with extracellular matrix components. J Exp Clin Cancer Res. 2004;23(4):641–650
  22. Juuti A, Nordling S, Lundin J, Louhimo J, Haglund C. Syndecan-1 expression-A Novel Prognostic Marker in Pancreatic Cancer. Oncology. 2005;68:97–106
  23. Acay RR, Felizzola CR, de Sousa SOM. Evaluation of proliferative potential in oral lichen planus and oral lichenoid lesions using immunohistochemical expression of p35 and ki67. J Oral Oncology. 2006;42:475–480
  24. Sulkowska M, Famulski W, Chyczewski L, Sulkowski S. Evaluation of p35 and bcl-2 oncoprotein expression in precancerous lesions of the oral cavity. Neoplasm. 2001;48:94–98
  25. Murti PR, Warnakulasuriya KAAS, Jonhnson NW, et al. p35 expression in oral precancer as a marker for malignant potential. J Oral Pathol Med. 1998;27:191–196
  26. Piatelli A, Rubini C, Fioroni M, Iezzi G, Santinelli A. Prevalence of p53, bcl- 2, and Ki-67 immunoreactivity and of apoptosis in normal oral epithelium and in premalignant and malignant lesions of the oral cavity. J Oral Maxillofac Surg. 2002;60(5):532–-540
  27. Schifter M, Jones AM, Walker DM. Epithelial p53 gene expression and mutational analysis, combined with growth fraction assessment, in oral lichen planus. J Oral Pathol Med. 1998;27:318–324
  28. Taniguchi Y, Nagao T, Maeda H, Kameyama Y, Warnakulasuriya KAAS. Epithelial cell proliferation in oral lichen planus. Cell Prolif. 2002;35(Suppl 1):103–109
  29. Valente G, Pagano M, Carrozzo M, et al. Sequential immunohistochemical p53 expression in biopsies of oral lichen planus undergoing malignant evolution. J Oral Pathol Med. 2001;30(3):135–140
  30. Scully C, Eisen D, Carrozzo M. Management of oral lichen planus. Am J Clin Dermatol. 2000;1:287–306
  31. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques a comparison between ABC and unlabled (antibody PAP) procedures. J Histochem Cytochem. 1981;29:577–580
  32. Kurokawa H, Matsumoto S, Murata T, et al. Immunohistochemical study of syndecan-1 down-regulation and the expression of p53 protein or Ki-67 antigen in oral leukoplakia with or without epithelial dysplasia. J Oral Pathol Med. 2003;32:513–521
  33. Krutchkoff DJ, Eisenberg E. Lichenoid dysplasia: a distinct histopathologic entity. Oral Surg Oral Med Oral Pathol. 1985;60:308–315
  34. Xue JL, Fan MW, Wang SZ, Chen XM, Li Y, Wang L. A clinical study of 674 patients with oral lichen planus in China. J Oral Pathol Med. 2005;34:467–472
  35. Bornstein MM, Kalas L, Lemp S, Altermatt HJ, Rees TD, Buser D. Oral lichen planus and malignant transformation: a retrospective follow-up study of clinical and histopathologic data. Quintessence Int. 2006;37:261–271
  36. Ingafou M, Leao JC, Porter SR, Scully C. Oral lichen planus: a retrospective study of 690 British patients. Oral Dis. 2006;12:463–468
  37. Hsue SS, Wang WC, Chen CH, Lin CC, Chen YK, Lin LM. Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: a follow- up study based in a Taiwanese hospital. J Oral Pathol Med. 2007;36:25–29
  38. Zhang JH, Zhou ZT. Oral lichen planus: a retrospective study of 724 Chinese patients. Zhonghua Kou Qiang Yi Xue Za Zhi. 2007;42:669–671
  39. Eisenberg E, Krutchkoff DJ. Lichenoid lesions of oral mucosa. Diagnostic criteria and their importance in the alleged relationship to oral cancer. Oral Surg Oral Med Oral Pathol. 1992;73:699–704
  40. Lanfranchi-Tizeira HE, Aguas SC, Sano SM. Malignant transformation of atypical oral lichen planus: a review of 32 cases. Med Oral. 2003;8:2–9
  41. Markopoulos AK, Antoniades D, Papanayotou P, Trigonidis G. Malignant potential of oral lichen planus: a follow-up study of 326 patients. J Oral Oncol. 1997;4:263–269
  42. Klanrit P, Thongprasom K, Rojanawatsirivej S, et al. Hepatitis C virus infection in Thai patients with oral lichen planus. Oral Dis. 2003;9:292–297
  43. Gimenz-Garcia R, Perez-Castrillon JL. Lichen planus and hepatitis C virus infection. J Eur Acad Dermatol Venereol. 2003;17:291–295
  44. Arrieta J, Rodriguez-Ingio E, Casqueiro M, Bartolome J, Manzarbeitia F, Herrerro M, et al. Detection of hepatitis C virus replication by in situ hybridization in epithelial cells of anti- hepatitis C virus-positive patients with and without oral lichen planus. Hepatology. 2000;32:97–103
  45. Femiano F, Scully C. Functions of the cytokines in relation oral lichen planus- hepatitis C. Med Oral Pathol Oral Cir Buccal. 2005;10:E40–E44
  46. Pilli M, Penna A, Zerbini A, Vescovi P, Manfredi M, Negro F, et al. Oral lichen planus pathogenesis: a role for the HCV-specific cellular immune response. Hepatology. 2002;36:1446–1452
  47. Hyrailles V, Peyron N, Planc P, Kark Y, Meunier L, Mey-nadier J, et al. Lichen planus and hepatitis C virus. Apropos of 5 new cases. Gastroenterol Clin Biol. 1995;19:833–836
  48. Nagao Y, Sata M, Abe K, Tanikawa K, Kameyama T. Immunological evaluation in oral lichen planus with chronic hepatitis C. J Gastroenterol. 1997;32:324–329
  49. Jaber MA, Porter SR, Bain L, Scully C. Lack of association between hepatitis C virus and oral epithelial dysplasia in British patients. Int J Oral Maxillofac Surg. 2003;32:181–183
  50. Roy KM, Dickson EM, Staines KS, Bagg J. Hepatitis C virus and oral lichen planus/lichenoid reactions: lack of evidence for an association. Clin Lab. 2000;46:251–254
  51. Van der Meij EH, Van der Waal I. Hepatitis C virus infection and oral lichen planus: a report from the Netherlands. J Oral Pathol Med. 2000;29(6):255–258
  52. Scully C, El-Korm M. Lichen planus: review and update on pathogenesis. J Oral Pathol. 1985;14:431–458
  53. Rebora A, Rongioletti F, Grosshans E. Lichen-hepatitis syndrome. General review apropos of a case. Ann Dermatol Venereol. 1985;112:27–32
  54. Sousa FA, Paradella TC, Carvalho YR, Rosa LE. Immunohistochemical expression of PCNA, p35, bax, and bcl-2 in oral lichen planus and epithelial dysplasia. J Oral Sci. 2009;51:117–121
  55. Greenblatt MS, Bennet WP, Hollstein M, et al. Mutations in the p35 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855–4878
  56. Hollstein M, Shomer B, Greenblatt M, et al. Somatic point mutations in the p35 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res. 1996;24:141–146
  57. Lane DP. P35, guardian of the genome. Nature. 1992;358:15–16
  58. Levine AJ. P35, the cellular gatekeeper for growth and division. Cell. 1997;88:323–331
  59. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 2000;6:357–362
  60. Sousa FA, Paradella TC, Carvalho YR, Rosa LEB. Comparative analysis of the expression of proliferating cell nuclear antigen, p35, bax, and bcl- 2 in oral lichen planus and oral squamous cell carcinoma. Ann Diagn Pathol. 2009;13:308–312
  61. Oliver R, MacDonald D. G1cyclins in oral epithelial dysplasia. J Oral Pathol Med. 2001;30:80–86
  62. Gonzalez-Moles MA, Gil-Montoya JA, Ruiz-Avila I, Esteban F, Bascones-Martinez A. Differences in the expression of p53 protein in oral lichen planus based on the use of monoclonal antibodies DO7 and pAb 240. Oral Oncol. 2008;44:496–503
  63. Ueda H, Ullrich S, Gangemi J, Kappel C, Ngo L, Feitelson M, et al. Functional inactivation but not structural mutation of p35 causes liver cancer. Nat Genet. 1995;9(1):41–47
  64. Ogmundsdottir H, Hilmarsdottir H, Astvaldsdottir A, Johannsson J, Holbrook W. Oral lichen planus has a high rate of TP53 mutations. A study of oral mucosa in Iceland. Eur J Oral Sci. 2002;110(3):192–198
  65. Cruz I, Napier S, Van der Waal I, et al. Suprabasal p35 immunoexpression is strongly associated with high grade dysplasia and risk for malignant transformation in potentially malignant oral lesions from Northern Ireland. J Clin Pathol. 2002;55:98–104
  66. Cruz I, Snijders P, Meijer C, et al. p35 expression above the basal cell layer is an early event of malignant transformation and has predictive value for developing squamous cell carcinoma. J Pathol. 1998;184:360–368
  67. Ray R, Steele R, Meyer K, Ray R. Transcriptional repression of p35 promoter by hepatitis C virus core protein. J Biol Chem. 1997;272(17):10983–10986
  68. Gong G, Jiang Y, Zhu Y, Su X. Regulation mechanism of HCV NS5A on p35 protein transactivity. Zhonghua Gan Zang Bing Za Zhi. 2003;11(3):162–165
  69. Florese R, Nagano-Fujii M, Iwanaga Y, Hidajat R, Hotta H. Inhibition of protein synthesis by the nonstructural proteins NS4A and NS4B of hepatitis C virus. Virus Res. 2002;90(1-2):119–131
  70. Staib F, Hussain S, Hofseth L, Wang X, Harris C. TP35 and liver carcinogenesis. Hum Mutat. 2003;21(3):201–216
  71. Souka T, Pohjola J, Inki , et al. Reduction of syndecan-1 expression is associated with dysplastic oral epithelium. J Oral Pathol Med. 2000;29:308–313

PII: S1092-9134(09)00167-1

doi: 10.1016/j.anndiagpath.2009.12.006

Annals of Diagnostic Pathology
Volume 14, Issue 3 , Pages 153-161 , June 2010

Article Tools

* Image Usage & Resolution